Stable Manufacturing and Ultralow-Temperature Logistics System for TEMCELL® HS Injection
First written in FY2016. 2 of 4 entries say "Advanced", first in FY2021. Latest entry: FY2022.
18 other companies' latest entry also says "Advanced".
- FY2022AdvancedAnnual report
「For Temcell® HS Injection, we strengthened the supply system in line with demand and became able to secure stable inventory. As a result, sales for the consolidated fiscal year increased by ¥1,055 million, or 43.2%, year on year.」
The supply system was strengthened in line with demand and stable inventory secured, resulting in a 43.2% year-on-year increase in sales of Temcell® HS Injection. - FY2021AdvancedAnnual report
「However, during the consolidated fiscal year, we strengthened the supply system in line with demand and became able to secure stable inventory. As a result, we expect sales to increase for the fiscal year ending March 2022.」
For Temcell® HS Injection, which was subject to supply restrictions from April to August 2020 because demand exceeded supply, the company strengthened its supply system and reached a position where stable inventory could be secured. - FY2020RestatedAnnual report
「Going forward, strengthening the supply system in line with demand is an issue.」
Following the expansion of Temcell® HS Injection sales, the company identified strengthening the supply system in line with demand as a future issue. No specific facility or logistics measures were reported as completed. - FY2016First statedAnnual report
「This product uses living cells and must be kept frozen in a specialized environment at temperatures of −130°C or below until immediately before use. We therefore jointly developed an ultra-low-temperature transport system using liquid nitrogen with Medipal Holdings Corporation, enabling us to deliver products of stable quality to clinical settings.」
A liquid-nitrogen transport system enabling storage and transportation at −130°C or below was jointly developed to stabilize product supplies.